bc3195
Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.Phase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 81/ 100
Competitive context
35 Active assets in the Locally Advanced or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atezolizumab Genentech, Inc. | Phase 2 | B |
Cyclophosphamide Exelixis | Phase 1/2 | CCC |
Talzenna Pfizer | Phase 2 | CCC |
gh21 Suzhou Genhouse Bio Co., Ltd. | Phase 2 | CCC |
Garsorasib Suzhou Genhouse Bio Co., Ltd. | Phase 2 | CCC |
View all 46 →
Same molecule, other indications
bc3195 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →